Phase 3 AQUILA study showed DARZALEX FASPRO ® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Â
CAPLYTA ® , in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications 1,2 Â
Johnson & Johnson (NYSE: JNJ) will present at the Citi’s 2025 Global Healthcare Conference on Wednesday, December 3 rd , 2025. Management will participate in a Fireside Chat at 11:15 a.m....
Learn key strategies and proven insights to earn steady income from your portfolio, courtesy of Barchart expert Rick Orford.
Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company
Kenvue stock has struggled this year, but an acquisition offer is giving investors hope leading up to this week's earnings report.
/Johnson%20%26%20Johnson%20logo%20on%20phone-by%20Allmy%20via%20Shutterstock.jpg)
Johnson & Johnson has delivered a standout performance in 2025, outperforming both the broader market and the healthcare sector. Analysts continue to be fairly bullish on the stock’s trajectory.
Three Dividend Kings with decades of dividend growth and strong financials are poised to deliver reliable income and stability for investors in 2025.
Patience and a tolerance for risk may be necessary, but these Hold stocks could eventually see big gains, according to analysts.